Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2023, the Group had a portfolio of 7 products in clinical development (including 3 in phase III, 3 in phase II and 1 in phase I), and 3 products in preclinical development.

Employees

298

Sector

Biotechnology & Medical Research

Calendar

2025-02-20 - Q4 2024 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
24-12-05	749.50 kr	+0.40%	79,179
24-12-04	746.50 kr	+2.26%	143,013
24-12-03	730.00 kr	+0.41%	162,372
24-12-02	727.00 kr	-0.41%	134,535
24-11-29	730.00 kr	0.00%	153,812

Delayed Quote Nasdaq Copenhagen, December 04, 2024 at 11:20 am EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart ZEALAND-PHARMA-A-S

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

746.50DKK

Average target price

1,015.00DKK

Spread / Average Target

+35.97%

Consensus

Profit revisions

estimates-change-chart ZEALAND-PHARMA-A-S

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart ZEALAND-PHARMA-A-S

Company calendar

Real-time Estimate Cboe Europe Other stock markets 09:01:24 2024-12-05 am EST			5-day change	1st Jan Change
751.00 ^DKK	+0.60%		+2.67%	+100.83%

Nov. 21	Zealand Pharma A/S Presents at Jefferies London Healthcare Conference 2024, Nov-21-2024 09:30 AM
Nov. 20	KBC Securities Initiates Zealand Pharma at Buy	MT

Capitalization	52.74B 7.45B 7.07B 6.58B 5.86B 10.48B 631B 11.57B 81.41B 30.26B 259B 27.97B 27.36B 1,118B	P/E ratio 2024 *	-60.1x	P/E ratio 2025 *	557x
Enterprise value	45.73B 6.46B 6.13B 5.7B 5.08B 9.09B 547B 10.03B 70.59B 26.24B 224B 24.26B 23.72B 970B	EV / Sales 2024 *	121x	EV / Sales 2025 *	25.3x
Free-Float	99.18%	Yield 2024 *	-	Yield 2025 *	-

Zealand Pharma A/S Presents at Jefferies London Healthcare Conference 2024, Nov-21-2024 09:30 AM	Nov. 21
KBC Securities Initiates Zealand Pharma at Buy	Nov. 20	MT
Zealand Pharma rallies after JP Morgan initiates Overweight rating	Nov. 08	FW
Danske Bank raises Zealand Pharma to 'Keep' (Sell), target price 825 Danish kroner - BN	Nov. 08	FW
Goldman Sachs lowers target price for Zealand Pharma to DKK 1,095 (1,106), reiterates Buy - BN	Nov. 08	FW
JP Morgan initiates coverage of Zealand Pharma with Overweight and target price of DKK 1,100 - BN	Nov. 08	FW
Zealand Pharma A/S, Q3 2024 Earnings Call, Nov 07, 2024	Nov. 07
Zealand Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 07	CI
Zealand Pharma reports promising results for weight loss drug - BN	Nov. 06	FW
Novo Nordisk share price falls after Viking Therapeutics pill update	Nov. 04	FW
Today's stock recommendations at a glance	Oct. 15	FW
Bank of America initiates coverage of Zealand Pharma with Buy and target price of DKK 1,100 - BN	Oct. 15	FW
Zealand Pharma falls after getting CRL from FDA	Oct. 09	FW

KBC Securities Initiates Zealand Pharma at Buy	Nov. 20	MT
Zealand Pharma rallies after JP Morgan initiates Overweight rating	Nov. 08	FW
Danske Bank raises Zealand Pharma to 'Keep' (Sell), target price 825 Danish kroner - BN	Nov. 08	FW
Goldman Sachs lowers target price for Zealand Pharma to DKK 1,095 (1,106), reiterates Buy - BN	Nov. 08	FW
JP Morgan initiates coverage of Zealand Pharma with Overweight and target price of DKK 1,100 - BN	Nov. 08	FW

Zealand Pharma A/S Stock

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Valuation: Zealand Pharma A/S

Chart: Zealand Pharma A/S

Latest news: Zealand Pharma A/S

Last Transcript: Zealand Pharma A/S

Analysts' recommendations: Zealand Pharma A/S

Press Releases: Zealand Pharma A/S

News in other languages: Zealand Pharma A/S

Quotes and Performance

Course Extremes

Managers and Directors: Zealand Pharma A/S

ETFs: Zealand Pharma A/S

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Zealand Pharma to participate in the Jefferies London Healthcare Conference	Nov. 13	GL
Zealand Pharma to participate in the Jefferies London Healthcare Conference	Nov. 13	AQ
Zealand Pharma A/S - Transactions in Zealand Pharma shares and or related securities by persons discharging managerial responsibilities and or their closely associated persons	Nov. 12	AQ
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons	Nov. 11	GL
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons	Nov. 11	AQ

Actualización de las fuertes variaciones del día: Continental anuncia buenas noticias; temores en Bayer	Oct. 09
Les actions en mouvement : Continental annonce de bonnes nouvelles ; craintes chez Bayer	Oct. 09
Chassez la géopolitique, elle revient au galop	Oct. 02
Avis d'analystes du jour : Kering, STMicro, Stellantis, Worldline, TotalEnergies, Unibail, Richemont...	Oct. 02
OPINIONI DEGLI ANALISTI DEL GIORNO: Brembo, Buzzi, Eni, STMicro, Stellantis, Generali, Moncler, Stellantis, Telecom Italia...	Oct. 02

1 day	+2.26%
1 week	+2.61%
Current month	+2.26%
1 month	-11.66%
3 months	-12.18%
6 months	+22.28%
Current year	+100.03%

Director	Title	Age	Since
Adam Sinding Steensberg CEO	Chief Executive Officer	50	2022-03-29
Henriette Wennicke DFI	Director of Finance/CFO	-	2022-10-31
David M. Kendall CTO	Chief Tech/Sci/R&D Officer	62	2022-06-01

Manager	Title	Age	Since
Alf Gunnar Martin Nicklasson CHM	Chairman	69	-
Kirsten Drejer BRD	Director/Board Member	68	2018-04-18
Bernadette Connaughton BRD	Director/Board Member	65	2019-04-03

Name	Weight	AuM	1st Jan change	Investor Rating
SIMPLIFY DEVELOPED EX-US PLUS DOWNSIDE CONVEXITY ETF - USD	0.01%	10 M€	-3.35%	-
RAREVIEW SYSTEMATIC EQUITY ETF - USD	0.00%	54 M€	0.00%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
ZEALAND PHARMA A/S	+2.26%	+2.61%	+119.30%	+455.43%	7.45B
VERTEX PHARMACEUTICALS INCORPORATED	+1.53%	-0.12%	+32.33%	+127.65%	119B
REGENERON PHARMACEUTICALS, INC.	+0.63%	-0.08%	-8.39%	+18.75%	81.15B
ARGENX SE	+0.27%	+1.27%	+40.00%	+131.75%	37.49B
BIONTECH SE	-0.77%	-4.99%	+14.80%	-66.66%	27.5B
BEIGENE, LTD.	-3.36%	-3.43%	+9.90%	-36.62%	21.15B
WUXI APPTEC CO., LTD.	-1.61%	+3.12%	-33.37%	-63.70%	20.27B
GENMAB A/S	-0.20%	+2.72%	-30.40%	-37.79%	13.71B
SUMMIT THERAPEUTICS INC.	-0.96%	-7.07%	+682.22%	+252.00%	12.98B
INSMED INCORPORATED	+4.05%	-0.69%	+179.42%	+191.08%	13.48B
Average	+0.18%	-0.60%	+100.58%	+97.19%	35.47B
Weighted average by Cap.	+0.49%	-0.49%	+46.15%	+74.82%

	2024 *	2025 *
Net sales	378M 53.34M 50.65M 47.11M 41.95M 75.06M 4.52B 82.87M 583M 217M 1.85B 200M 196M 8.01B	1.77B 250M 237M 221M 197M 352M 21.18B 388M 2.73B 1.02B 8.69B 939M 919M 37.55B
Net income	-774M -109M -104M -96.6M -86.02M -154M -9.27B -170M -1.2B -444M -3.8B -411M -402M -16.42B	226M 31.86M 30.26M 28.14M 25.06M 44.84M 2.7B 49.51M 348M 129M 1.11B 120M 117M 4.78B
Net Debt	-7.01B -990M -940M -874M -778M -1.39B -83.85B -1.54B -10.82B -4.02B -34.39B -3.72B -3.64B -149B	-8.02B -1.13B -1.08B -1B -890M -1.59B -95.92B -1.76B -12.38B -4.6B -39.34B -4.25B -4.16B -170B